Cargando…
Natural History of Pediatric Patients With Crohn’s Disease Treated With Mesalamine Therapy
BACKGROUND: 5-aminosalicylates (5-ASA) are used to treat mild to moderate ulcerative colitis. Despite their lack of efficacy in Crohn disease (CD), they are still used in real-world practice. Additionally, when patients have progressive disease, they may escalate to biologic therapy, at which time 5...
Autores principales: | Young, Denise D., Perry, Sharon, Malay, Sindhoosha, Sferra, Thomas J., Finkler, Michael, Moses, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684219/ https://www.ncbi.nlm.nih.gov/pubmed/38034435 http://dx.doi.org/10.1097/PG9.0000000000000379 |
Ejemplares similares
-
Association of Fecal Calprotectin With Endoscopic and Histologic Activity in Pediatric Inflammatory Bowel Disease
por: Crawford, Erin, et al.
Publicado: (2021) -
Mesalamine Intolerance in Three Children with Crohn's Disease
por: Tuna Kirsaclioglu, Ceyda, et al.
Publicado: (2016) -
Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease
por: Kwak, Min Seob, et al.
Publicado: (2018) -
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
por: Doherty, Glen A, et al.
Publicado: (2009) -
Intrahepatic cholestasis in Bruton's agammaglobulinemia receiving mesalamine for co-morbid Crohn's disease
por: Actis, Giovanni Clemente, et al.
Publicado: (2014)